Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 20/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 12/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.81 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13953556 | 1.00 | HSD11B1 (0.81) | HSD11B1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL957557 | 0.91 | HSD11B1 (0.83) | HSD11B1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL957558 | 0.91 | HSD11B1 (0.83) | HSD11B1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL15959057 | 0.91 | HSD11B1 (0.83) | HSD11B1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL959352 | 0.90 | HSD11B1 (0.94) | HSD11B1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL992276 | 0.90 | HSD11B1 (1.00) | HSD11B1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL117440 | 0.90 | HSD11B1 (1.00) | HSD11B1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL956668 | 0.90 | HSD11B1 (0.81) | HSD11B1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL117441 | 0.90 | HSD11B1 (1.00) | HSD11B1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL12188092 | 0.90 | HSD11B1 (0.81) | HSD11B1CYP2C9CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232050-A1 | Cyclic Inhibitors of 11 beta-Hydroxysteroid Dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| EP-2183229-B1 | SYNTHESIS OF INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS INC (US) | 2012-04-18 | — | — | EP | disclosed |
| US-20120040973-A1 | DERIVATIVES OF [1,3]OXAZIN-2-ONE USEFUL FOR THE TREATMENT OF METABOLIC DISEASES SUCH AS LIPID DISORDERS | VITAE PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20110269957-A1 | SYNTHESIS OF INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| WO-2009017664-A1 | CYCLIC INHIBITORS OF 11β-HYDROXYSTERIOD DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269957-A1 | SYNTHESIS OF INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885CYP2C9 528/4885CYP3A4 390/4885 |
| US-20120040973-A1 | DERIVATIVES OF [1,3]OXAZIN-2-ONE USEFUL FOR THE TREATMENT OF METABOLIC DISEASES SUCH AS LIPID DISORDERS | HSD11B1, HSD11B2, HSD17B1 | HSD11B1 1/4885CYP2C9 229/4885CYP3A4 172/4885 |
| US-20120232050-A1 | Cyclic Inhibitors of 11 beta-Hydroxysteroid Dehydrogenase 1 | HSD11B1, HSD3B1, HSD11B2 | HSD11B1 1/4885CYP2C9 115/4885CYP3A4 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.